+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dyskinesia Market - Global Forecast to 2030- Product Image
Dyskinesia Market - Global Forecast to 2030- Product Image
New

Dyskinesia Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 185 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6082614
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Dyskinesia Market grew from USD 3.42 billion in 2024 to USD 3.66 billion in 2025. It is expected to continue growing at a CAGR of 7.30%, reaching USD 5.23 billion by 2030.

Executive Summary Introduction: Dyskinesia Market Overview

Dyskinesia represents a spectrum of involuntary, hyperkinetic movements that profoundly affect millions of patients worldwide, emerging as a critical challenge for neurologists, rehabilitation specialists, and healthcare decision-makers. This executive summary distills the multifaceted dynamics of the dyskinesia landscape, offering a concise yet comprehensive overview of its evolving treatment paradigms, market drivers, and key differentiators. By examining technological innovations, regulatory shifts, and supply-chain complexities, it establishes a foundational understanding of how therapeutic modalities are advancing and converging. Through a structured analysis of segmentation, regional performance, corporate strategies, and policy influences, readers will gain actionable insights to inform investment decisions, research priorities, and partnership strategies. Recognizing the growing burden of dyskinesia in both Parkinsonian and non-Parkinsonian populations, this summary highlights critical inflection points and emerging opportunities. Ultimately, it sets the stage for deeper exploration of transformative shifts, tariff impacts, and strategic imperatives that shape the future of dyskinesia care.

Transformative Shifts in the Dyskinesia Treatment Landscape

In recent years, the dyskinesia landscape has undergone transformative shifts driven by scientific breakthroughs and patient-centric care models. Advances in precision medicine have enabled tailored pharmacological regimens, while real-world data analytics inform adaptive dosing strategies. Concurrently, breakthrough neuromodulation techniques, such as next-generation deep brain stimulation platforms, are redefining surgical interventions by offering closed-loop feedback and enhanced targeting. In parallel, digital therapeutics and tele-rehabilitation programs have expanded non-pharmacological care beyond traditional clinic walls, improving access and adherence. Regulatory bodies are increasingly endorsing novel endpoints, accelerating the approval of compounds that modulate synaptic neurotransmitter levels with unprecedented specificity. Additionally, collaboration between device manufacturers and biotech firms is fostering hybrid solutions that integrate drug delivery with monitoring sensors. Taken together, these shifts underscore a future in which multidisciplinary approaches converge to optimize safety, efficacy, and patient engagement across the dyskinesia continuum.

Cumulative Impact of United States Tariffs 2025 on Treatment Costs and Supply Chains

The imposition of new United States tariffs in 2025 has triggered notable repercussions across the dyskinesia treatment ecosystem, affecting inputs ranging from active pharmaceutical ingredients to implantable neuromodulation hardware. Manufacturers have faced increased costs for imported raw materials, prompting many to reassess their global sourcing strategies. As a result, several leading pharmaceutical and device companies are localizing production and negotiating long-term supplier agreements to hedge against further tariff volatility. Meanwhile, logistics providers are optimizing distribution networks by consolidating shipments and leveraging nearshore facilities to mitigate delays. Payers and health systems, confronted with elevated acquisition costs, are tightening formulary criteria and demanding value-based contracting models that link reimbursement to real-world patient outcomes. Consequently, market entrants are prioritizing demonstration of clear clinical and economic benefits to secure market access. These cumulative effects underscore the importance of supply-chain resilience and strategic pricing frameworks in sustaining innovation and ensuring patient affordability.

Key Segmentation Insights for the Dyskinesia Market

When dissecting the dyskinesia market by treatment type, non-pharmacological approaches encompass both behavioral therapy and physical therapy & rehabilitation, reflecting a holistic emphasis on movement retraining and neuromuscular reconditioning. In the realm of pharmacological treatments, a diverse array of agents-anticholinergics, dopamine modulators, GABA agonists, NMDA receptor antagonists, and VMAT2 inhibitors-address distinct neurotransmitter pathways to attenuate hyperkinetic movements. Surgical interventions, particularly ablative surgery and deep brain stimulation, continue to evolve through less invasive techniques and adaptive stimulation systems. Examining dyskinesia by type reveals subcategories such as athetosis, chorea, dystonia-related dyskinesia, myoclonic dyskinesia, Parkinson’s dyskinesia, spasmodic torticollis, and tardive dyskinesia, each presenting unique treatment challenges and research priorities. Moreover, the route of administration spans intravenous and infusion-based therapies, oral formulations, subcutaneous injections, and transdermal systems, enabling customized delivery profiles aligned with patient preferences and clinical requirements. Finally, patient care settings-from home care environments to hospitals, research institutes, specialty clinics, and rehabilitation centers-dictate variations in service models, resource allocation, and care coordination. This multi-layered segmentation framework illuminates the nuanced needs of distinct patient cohorts and guides targeted innovation.

Key Regional Insights Highlighting Global Opportunities

In the Americas, robust reimbursement frameworks and a mature payer ecosystem have accelerated adoption of advanced dyskinesia therapies, while leading centers of excellence continue to publish outcome data that shape global standards of care. Transitioning to Europe, Middle East & Africa, heterogeneous regulatory pathways present both challenges and opportunities; established markets benefit from standardized pricing negotiations, whereas emerging economies are witnessing pilot programs for mobile rehabilitation and telemonitoring. Meanwhile, in Asia-Pacific, demographic shifts and rising healthcare investment have fueled increased screening and early intervention initiatives, especially in urban centers where deep brain stimulation programs are scaling rapidly. Regional supply-chain diversification efforts are underway to mitigate tariff-related disruptions, with cross-border manufacturing partnerships enhancing accessibility in cost-sensitive markets. Across all territories, collaborative research consortia and public-private partnerships are driving localized clinical trials, fostering innovation that addresses region-specific epidemiological trends and healthcare infrastructure dynamics.

Key Company Insights Driving Innovation and Competitive Dynamics

Innovation in the dyskinesia arena is propelled by a diverse roster of industry leaders and emerging biotechs alike. Global medtech giants such as Abbott Laboratories, Medtronic PLC, and Toray Industries, Inc. are expanding their neuromodulation portfolios with next-generation implantable devices that offer closed-loop capabilities. Major pharmaceutical firms including AbbVie Inc., Teva Pharmaceutical Industries Ltd., and Zydus Lifesciences Limited continue to optimize small-molecule therapies with enhanced safety profiles. Biotechnology innovators like Addex Therapeutics Ltd., IRLAB Therapeutics AB, and Neurolixis Inc. are advancing first-in-class compounds targeting novel neurotransmitter receptors, while developmental-stage companies such as PharmaTher Holdings Ltd., Prilenia Therapeutics B.V., and ReCode Therapeutics, Inc. focus on epigenetic and RNA-based approaches. Additionally, specialist actors including Clearmind Medicine Inc., Melior Pharmaceuticals, and Serina Therapeutics, Inc. are pioneering non-invasive neuromodulation and psychedelic-informed modalities. Meanwhile, device-pharma hybrids from Motac France Sarl and Mitsubishi Tanabe Pharma Corporation illustrate the growing trend toward integrated therapeutic platforms. Collaborations involving Neurocrine Biosciences, Inc., Supernus Pharmaceuticals, Inc., and Vistagen Therapeutics, Inc. are exploring combination regimens, and research endeavors by Bukwang Pharmaceutical Co., Ltd, Luye Pharma Group Ltd., SOM INNOVATION BIOTECH, SA, Voyager Therapeutics, Inc., and Ipsen Pharma SAS underscore the breadth of global investment in this space.

Actionable Recommendations for Industry Leaders

Industry leaders must adopt a multi-pronged strategy to thrive in the competitive dyskinesia landscape. First, forging alliance networks between pharmaceutical developers and medtech firms can accelerate co-development of integrated drug-device solutions, leveraging each partner’s core competencies. Second, investing in real-world evidence generation will strengthen value propositions for payers, enabling value-based reimbursement and enhancing long-term market access. Third, diversifying supply chains through regional manufacturing hubs and nearshore partnerships will mitigate tariff-related risks and ensure continuity of critical inputs. Fourth, prioritizing digital health ecosystems-such as telemonitoring platforms and AI-driven symptom tracking-will boost patient engagement and adherence, ultimately improving clinical outcomes. Fifth, aligning R&D investments with patient subgroups defined by dyskinesia type and care setting will optimize resource allocation and heighten therapeutic precision. By executing these interdependent initiatives in concert, industry players can reinforce competitive differentiation, drive sustainable growth, and deliver meaningful benefits to patients.

Conclusion: Integrating Insights for Strategic Advantage

In conclusion, the dyskinesia market is at an inflection point where scientific advances, regulatory evolution, and market forces converge to shape next-generation care pathways. Technological breakthroughs in both pharmacological and neuromodulation domains are expanding treatment options, while digital and real-world evidence frameworks are redefining value capture. Tariff-induced supply-chain challenges underscore the imperative for regional production strategies and robust pricing models. A nuanced understanding of segmentation-spanning treatment types, dyskinesia subtypes, administration routes, and care settings-enables more targeted innovation and patient engagement. Regional insights reveal differentiated growth trajectories across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each demanding tailored approaches. Finally, an ecosystem of established and emerging companies is driving competition and collaboration, offering a fertile ground for strategic alliances. By integrating these insights into holistic roadmaps, stakeholders can anticipate market shifts, optimize investment decisions, and ultimately advance the standard of care for patients living with dyskinesia.

Market Segmentation & Coverage

This research report categorizes the Dyskinesia Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Non-Pharmacological Approaches
    • Behavioral Therapy
    • Physical Therapy & Rehabilitation
  • Pharmacological Treatments
    • Anticholinergics
    • Dopamine Modulators
    • GABA Agonists
    • NMDA Receptor Antagonists
    • VMAT2 Inhibitors
  • Surgical Treatments
    • Ablative Surgery
    • Deep Brain Stimulation (DBS)
  • Athetosis
  • Chorea
  • Dystonia-Related Dyskinesia
  • Myoclonic Dyskinesia
  • Parkinson’s Dyskinesia
  • Spasmodic Torticollis
  • Tardive Dyskinesia
  • Intravenous (IV) & Infusion-Based
  • Oral
  • Subcutaneous
  • Transdermal
  • Home Care
  • Hospitals
  • Research Institutes
  • Specialty Clinics & Rehabilitation Centers

This research report categorizes the Dyskinesia Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Dyskinesia Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • AbbVie Inc.
  • Addex Therapeutics Ltd.
  • Bukwang Pharmaceutical Co., Ltd
  • Clearmind Medicine Inc.
  • Ipsen Pharma SAS
  • IRLAB Therapeutics AB
  • Luye Pharma Group Ltd.
  • Medtronic PLC
  • Melior Pharmaceuticals
  • Mitsubishi Tanabe Pharma Corporation
  • Motac France Sarl
  • Neurocrine Biosciences, Inc.
  • Neurolixis Inc.
  • PharmaTher Holdings Ltd.
  • Prilenia Therapeutics B.V.
  • ReCode Therapeutics, Inc.
  • Serina Therapeutics, Inc.
  • SOM INNOVATION BIOTECH, SA
  • Supernus Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Toray Industries, Inc.
  • Vistagen Therapeutics, Inc.
  • Voyager Therapeutics, Inc.
  • Zydus Lifesciences Limited

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Dyskinesia Market, by Treatment Type
8.1. Introduction
8.2. Non-Pharmacological Approaches
8.2.1. Behavioral Therapy
8.2.2. Physical Therapy & Rehabilitation
8.3. Pharmacological Treatments
8.3.1. Anticholinergics
8.3.2. Dopamine Modulators
8.3.3. GABA Agonists
8.3.4. NMDA Receptor Antagonists
8.3.5. VMAT2 Inhibitors
8.4. Surgical Treatments
8.4.1. Ablative Surgery
8.4.2. Deep Brain Stimulation (DBS)
9. Dyskinesia Market, by Dyskinesia Type
9.1. Introduction
9.2. Athetosis
9.3. Chorea
9.4. Dystonia-Related Dyskinesia
9.5. Myoclonic Dyskinesia
9.6. Parkinson’s Dyskinesia
9.7. Spasmodic Torticollis
9.8. Tardive Dyskinesia
10. Dyskinesia Market, by Route of Administration
10.1. Introduction
10.2. Intravenous (IV) & Infusion-Based
10.3. Oral
10.4. Subcutaneous
10.5. Transdermal
11. Dyskinesia Market, by Patient Care Settings
11.1. Introduction
11.2. Home Care
11.3. Hospitals
11.4. Research Institutes
11.5. Specialty Clinics & Rehabilitation Centers
12. Americas Dyskinesia Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Dyskinesia Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Dyskinesia Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Abbott Laboratories
15.3.2. AbbVie Inc.
15.3.3. Addex Therapeutics Ltd.
15.3.4. Bukwang Pharmaceutical Co., Ltd
15.3.5. Clearmind Medicine Inc.
15.3.6. Ipsen Pharma SAS
15.3.7. IRLAB Therapeutics AB
15.3.8. Luye Pharma Group Ltd.
15.3.9. Medtronic PLC
15.3.10. Melior Pharmaceuticals
15.3.11. Mitsubishi Tanabe Pharma Corporation
15.3.12. Motac France Sarl
15.3.13. Neurocrine Biosciences, Inc.
15.3.14. Neurolixis Inc.
15.3.15. PharmaTher Holdings Ltd.
15.3.16. Prilenia Therapeutics B.V.
15.3.17. ReCode Therapeutics, Inc.
15.3.18. Serina Therapeutics, Inc.
15.3.19. SOM INNOVATION BIOTECH, SA
15.3.20. Supernus Pharmaceuticals, Inc.
15.3.21. Teva Pharmaceutical Industries Ltd.
15.3.22. Toray Industries, Inc.
15.3.23. Vistagen Therapeutics, Inc.
15.3.24. Voyager Therapeutics, Inc.
15.3.25. Zydus Lifesciences Limited
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. DYSKINESIA MARKET MULTI-CURRENCY
FIGURE 2. DYSKINESIA MARKET MULTI-LANGUAGE
FIGURE 3. DYSKINESIA MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DYSKINESIA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DYSKINESIA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES DYSKINESIA MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES DYSKINESIA MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. DYSKINESIA MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. DYSKINESIA MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DYSKINESIA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DYSKINESIA MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DYSKINESIA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DYSKINESIA MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DYSKINESIA MARKET SIZE, BY PHYSICAL THERAPY & REHABILITATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DYSKINESIA MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DYSKINESIA MARKET SIZE, BY DOPAMINE MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DYSKINESIA MARKET SIZE, BY GABA AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DYSKINESIA MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DYSKINESIA MARKET SIZE, BY VMAT2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DYSKINESIA MARKET SIZE, BY ABLATIVE SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DYSKINESIA MARKET SIZE, BY DEEP BRAIN STIMULATION (DBS), BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DYSKINESIA MARKET SIZE, BY ATHETOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DYSKINESIA MARKET SIZE, BY CHOREA, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DYSKINESIA MARKET SIZE, BY DYSTONIA-RELATED DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DYSKINESIA MARKET SIZE, BY MYOCLONIC DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DYSKINESIA MARKET SIZE, BY PARKINSON’S DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DYSKINESIA MARKET SIZE, BY SPASMODIC TORTICOLLIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DYSKINESIA MARKET SIZE, BY TARDIVE DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DYSKINESIA MARKET SIZE, BY INTRAVENOUS (IV) & INFUSION-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DYSKINESIA MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DYSKINESIA MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DYSKINESIA MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DYSKINESIA MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DYSKINESIA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DYSKINESIA MARKET SIZE, BY SPECIALTY CLINICS & REHABILITATION CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 62. CANADA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 63. CANADA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 64. CANADA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 65. CANADA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 66. CANADA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 67. CANADA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. CANADA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 69. MEXICO DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 70. MEXICO DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 71. MEXICO DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 72. MEXICO DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 73. MEXICO DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. MEXICO DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES DYSKINESIA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 84. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 85. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 86. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 87. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 88. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 89. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 92. AUSTRALIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 93. AUSTRALIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 94. AUSTRALIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 95. AUSTRALIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 96. AUSTRALIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 97. AUSTRALIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. AUSTRALIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 99. CHINA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 100. CHINA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 101. CHINA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 102. CHINA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 103. CHINA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 104. CHINA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. CHINA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 106. INDIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 107. INDIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 108. INDIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 109. INDIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 110. INDIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 111. INDIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. INDIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 113. INDONESIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 114. INDONESIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 115. INDONESIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 116. INDONESIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 117. INDONESIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 118. INDONESIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. INDONESIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 120. JAPAN DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 121. JAPAN DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 122. JAPAN DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 123. JAPAN DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 124. JAPAN DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 125. JAPAN DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. JAPAN DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 127. MALAYSIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 128. MALAYSIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 129. MALAYSIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 130. MALAYSIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 131. MALAYSIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 132. MALAYSIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. MALAYSIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 134. PHILIPPINES DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 135. PHILIPPINES DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 136. PHILIPPINES DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 137. PHILIPPINES DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 138. PHILIPPINES DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 139. PHILIPPINES DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. PHILIPPINES DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 141. SINGAPORE DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 142. SINGAPORE DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 143. SINGAPORE DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 144. SINGAPORE DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 145. SINGAPORE DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 146. SINGAPORE DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. SINGAPORE DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 148. SOUTH KOREA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 149. SOUTH KOREA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 150. SOUTH KOREA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 151. SOUTH KOREA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 152. SOUTH KOREA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 153. SOUTH KOREA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. SOUTH KOREA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 155. TAIWAN DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 156. TAIWAN DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 157. TAIWAN DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 158. TAIWAN DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 159. TAIWAN DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 160. TAIWAN DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. TAIWAN DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 162. THAILAND DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 163. THAILAND DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 164. THAILAND DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 165. THAILAND DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 166. THAILAND DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 167. THAILAND DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. THAILAND DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 169. VIETNAM DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 170. VIETNAM DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 171. VIETNAM DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 172. VIETNAM DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 173. VIETNAM DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 174. VIETNAM DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. VIETNAM DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 184. DENMARK DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 185. DENMARK DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 186. DENMARK DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 187. DENMARK DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 188. DENMARK DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 189. DENMARK DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. DENMARK DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 191. EGYPT DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 192. EGYPT DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 193. EGYPT DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 194. EGYPT DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 195. EGYPT DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 196. EGYPT DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. EGYPT DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 198. FINLAND DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 199. FINLAND DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 200. FINLAND DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 201. FINLAND DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 202. FINLAND DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 203. FINLAND DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. FINLAND DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 205. FRANCE DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 206. FRANCE DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 207. FRANCE DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 208. FRANCE DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 209. FRANCE DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 210. FRANCE DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. FRANCE DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 212. GERMANY DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 213. GERMANY DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 214. GERMANY DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 215. GERMANY DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 216. GERMANY DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 217. GERMANY DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. GERMANY DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 219. ISRAEL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 220. ISRAEL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 221. ISRAEL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 222. ISRAEL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 223. ISRAEL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 224. ISRAEL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. ISRAEL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 226. ITALY DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 227. ITALY DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 228. ITALY DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 229. ITALY DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 230. ITALY DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 231. ITALY DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. ITALY DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 233. NETHERLANDS DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 234. NETHERLANDS DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 235. NETHERLANDS DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 238. NETHERLANDS DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. NETHERLANDS DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 243. NIGERIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 244. NIGERIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 245. NIGERIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. NIGERIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 247. NORWAY DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 248. NORWAY DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 249. NORWAY DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 250. NORWAY DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 251. NORWAY DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 252. NORWAY DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. NORWAY DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 254. POLAND DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 255. POLAND DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 256. POLAND DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 257. POLAND DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 258. POLAND DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 259. POLAND DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. POLAND DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 261. QATAR DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 262. QATAR DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 263. QATAR DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 264. QATAR DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 265. QATAR DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 266. QATAR DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 267. QATAR DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 268. RUSSIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 269. RUSSIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 270. RUSSIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 271. RUSSIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 272. RUSSIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 273. RUSSIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. RUSSIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 276. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 278. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 280. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 282. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 284. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 286. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 288. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 289. SPAIN DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 290. SPAIN DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 291. SPAIN DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 292. SPAIN DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 293. SPAIN DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 294. SPAIN DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 295. SPAIN DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 296. SWEDEN DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 297. SWEDEN DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 298. SWEDEN DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 299. SWEDEN DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 300. SWEDEN DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 301. SWEDEN DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 302. SWEDEN DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 303. SWITZERLAND DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 304. SWITZERLAND DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 305. SWITZERLAND DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 306. SWITZERLAND DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 307. SWITZERLAND DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 308. SWITZERLAND DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 309. SWITZERLAND DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 310. TURKEY DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 311. TURKEY DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 312. TURKEY DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 313. TURKEY DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 314. TURKEY DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 315. TURKEY DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 316. TURKEY DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 317. UNITED ARAB EMIRATES DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 318. UNITED ARAB EMIRATES DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 319. UNITED ARAB EMIRATES DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 324. UNITED KINGDOM DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 325. UNITED KINGDOM DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 326. UNITED KINGDOM DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 327. UNITED KINGDOM DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 328. UNITED KINGDOM DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 329. UNITED KINGDOM DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 330. UNITED KINGDOM DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 331. DYSKINESIA MARKET SHARE, BY KEY PLAYER, 2024
TABLE 332. DYSKINESIA MARKET, FPNV POSITIONING MATRIX, 2024

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Addex Therapeutics Ltd.
  • Bukwang Pharmaceutical Co., Ltd
  • Clearmind Medicine Inc.
  • Ipsen Pharma SAS
  • IRLAB Therapeutics AB
  • Luye Pharma Group Ltd.
  • Medtronic PLC
  • Melior Pharmaceuticals
  • Mitsubishi Tanabe Pharma Corporation
  • Motac France Sarl
  • Neurocrine Biosciences, Inc.
  • Neurolixis Inc.
  • PharmaTher Holdings Ltd.
  • Prilenia Therapeutics B.V.
  • ReCode Therapeutics, Inc.
  • Serina Therapeutics, Inc.
  • SOM INNOVATION BIOTECH, SA
  • Supernus Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Toray Industries, Inc.
  • Vistagen Therapeutics, Inc.
  • Voyager Therapeutics, Inc.
  • Zydus Lifesciences Limited

Methodology

Loading
LOADING...

Related Topics

Related Reports

Dyskinesia - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Dyskinesia - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Tardive Dyskinesia - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Tardive Dyskinesia - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Primary Ciliary Dyskinesia Market 2024-2028 - Product Image

Primary Ciliary Dyskinesia Market 2024-2028

  • Report
  • 193 Pages
  • Global
From
Primary Ciliary Dyskinesia Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Primary Ciliary Dyskinesia Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 82 Pages
  • Global
From

About the Dyskinesia Market

Dyskinesia is a neurological disorder characterized by involuntary, repetitive movements. It is most commonly associated with the use of certain central nervous system drugs, such as antipsychotics and levodopa. Dyskinesia can cause a range of physical symptoms, including jerky movements, tremors, and difficulty with coordination. It can also lead to psychological symptoms, such as anxiety and depression. The dyskinesia market is composed of a range of pharmaceutical companies that produce drugs to treat the disorder. These companies develop and market medications that can reduce the severity of symptoms and improve quality of life. Many of these drugs are approved by the FDA and are available in both generic and brand-name forms. Some of the companies in the dyskinesia market include AbbVie, Allergan, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.